Nothing said here yet.
to join the conversation.
Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker with pipeline-in-a-product opportunity…
The tie-up marks the latest pharma company to enlist the AI-powered drug discovery services of Generate.
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early…
Zealand Pharma shares have fallen sharply over the past year, which puts fresh focus on whether the current price still lines up with what the business earns.
Zealand Pharma (CPSE:ZEAL) is back in focus after reporting that its Phase 2 ZUPREME-2 trial for petrelintide met the primary endpoint, showing meaningful weight loss and HbA1c improvements in adults with type 2 diabetes.
The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.
Zealand Pharma (CPSE:ZEAL) reported positive topline Phase 2 ZUPREME-2 data for its amylin analog petrelintide in adults with overweight or obesity and type 2 diabetes.
Company announcement – No. 54 / 2026 Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes Petrelintide achieved up to 9.2% mean body weight reduction at…
Company announcement No. 53 / 2026 Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026) Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
Ribbon cutting ceremony Officially inauguration of Zealand Pharma Research Hub in Cambridge, MA.(From left: Eric Rojas, VP, Head of Investor Relations, Zealand Pharma; Yi-An Huang, Cambridge City Manager; Christina Sonnenborg Bredal, Chief People Officer,…
Zealand Pharma (ZEAL) said Thursday that Boehringer Ingelheim's survodutide achieved up to 13.1% ave
Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes In the…